Hari Kumar

Dr. Kumar has over 25 years of pharmaceutical experience. He spent a number of years at Hoffmann La Roche starting in basic research and then moving to sales and marketing, lifecycle management, and finally to business development. During the period 1996 through 1999, Dr. Kumar moved to Eisai Ltd, as their European Marketing Director before returning to Roche in 1999.

He moved to Amira Pharmaceuticals, Inc. in 2007 as Chief Business Officer and after Amira’s acquisition in 2011 by Bristol Myers Squibb, became Chief Executive Officer of Panmira Pharmaceuticals LLC.

In his time, Dr. Kumar has overseen the launch of the immunosuppressive, CellCept®, the Alzheimer’s drug, Aricept® and gastric ulcer drug, Aciphex®. He was also involved in guiding cross-functional teams at Roche for the Transplantation franchise which resulted in the growth of the products in the franchise to achieve billion-dollar sales. He was instrumental in partnerships with Isotechnika, Biotie, Biocryst, and Actellion.

Dr. Kumar is a trained immunologist from University College London where he completed his Ph.D. under the supervision of Professor N.A. Mitchison and completed a postdoctoral fellowship at Tufts-New England Medical Center in Boston and at the Marie Curie Cancer Research Centre in the UK.